Pixium Vision convenes its Annual Meeting of Shareholders on June 13, 2023
Paris, France, May 10, 2023 – 07:00 p.m. CET – Pixium Vision SA (Euronext Growth Paris - FR0011950641), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces that it will hold its annual meeting of shareholders at 14:00 CET on June 13, 2023 at Pixium Vision’s headquarter office. The meeting will take place in person.
The notice of the meeting published in the BALO (Bulletin des Annonces Légales Obligatoires) n°55 on May 8 2023 is available on the Company’s website (www.pixium-vision.com) under «Shareholders’ General Meeting».
Information and documents relating to the Annual Meeting will be available on the Company's website as from the convening of the shareholders in accordance with applicable laws and regulations.
About Pixium Vision
Pixium Vision is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy. Pixium Vision’s bionic vision systems are associated with a surgical intervention and a rehabilitation period. Prima System sub-retinal miniature photovoltaic wireless implant is in clinical testing for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners, including some of the most prestigious vision research institutions in the world, such as Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, Institute of Ocular Microsurgery (IMO) in Barcelona, University hospital in Bonn, and UPMC in Pittsburgh, PA. The Company is EN ISO 13485 certified and qualifies as “Entreprise Innovante” by Bpifrance.
For more information: http://www.pixium-vision.com/fr
Follow us on @PixiumVision; www.facebook.com/pixiumvision
www.linkedin.com/company/pixium-vision
Contacts
| Investor Relations Pixium Vision Offer Nonhoff investors@pixium-vision.com | Media Relations Rose Piquante Consulting Sophie Baumont sophie.baumont@rosepiquante-consulting.com +33 6 27 74 74 49 |
Attachment
